<DOC>
	<DOCNO>NCT00414440</DOCNO>
	<brief_summary>This study ass whether everolimus ( RAD001 ) effective prevent cyst kidney expansion well worsen renal function patient ADPKD whether application 5 mg/day everolimus monotherapy safe well tolerate .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Everolimus Preventing End-stage Renal Disease Patients With Autosomal Dominant Polycystic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria 1 . Clinical diagnosis autosomal dominant polycystic kidney disease ADPKD 2 . Chronic kidney disease ( CKD ) stage II / III 3 . Females capable become pregnant must negative serum pregnancy test within 7 day prior baseline , required practice approve method birth control duration study period 6 week follow discontinuation study medication , even history infertility Exclusion Criteria 1 . ADPKD patient normal renal function 2 . ADPKD patient CKD stage IV 3 . Patients history subarachnoid bleeding 4 . Patients history severe infection 5 . Patients lifethreatening urinary tract cyst infection past 6 . Patients receive investigational drug within four week prior baseline 7 . Patients treat nonprotocol immunosuppressive drug treatment within one month prior baseline Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>end-stage renal disease , ESRD , autosomal dominant polycystic kidney disease , ADPKD , everolimus</keyword>
</DOC>